(EOLS) Evolus - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30052C1071
EOLS: Botulinum Toxin, Dermal Fillers
Evolus Inc (NASDAQ:EOLS) operates in the cash-pay aesthetic market, offering products that consumers purchase out-of-pocket, a strategy that influences their pricing and market approach. Their flagship product, Jeuveau, is a 900 kDa purified botulinum toxin type A, positioning it as a competitor to Botox. This unique molecular size is a key differentiator, supported by a strong intellectual property portfolio crucial for market protection.
Financially, Evolus has a market cap of approximately $952 million, indicating a mid-sized company. The P/E ratio is currently zero, suggesting they are not yet profitable. However, a forward P/E of 33.44 hints at expected growth. The high P/B ratio of 161.69 may raise eyebrows, reflecting market expectations for future growth, though it comes with risks if growth falters. The P/S ratio of 3.84 shows revenue generation, yet the valuation may be steep.
Evolus diversifies its offerings with dermal fillers like Estyme and Evolysse, reducing reliance on neurotoxins. Their international presence spans the US, Canada, and Europe, with Nuceiva approved in Europe but not yet in the US. Strategic manufacturing partnerships, such as with Daewoong, underscore their operational efficiency. Investors should consider their competitive stance against major players like Allergan, their IP strength, and strategic partnerships when assessing potential.
Additional Sources for EOLS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EOLS Stock Overview
Market Cap in USD | 858m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2018-02-08 |
EOLS Stock Ratings
Growth 5y | 59.6% |
Fundamental | -14.9% |
Dividend | 0.0% |
Rel. Strength Industry | -7.01 |
Analysts | 4.43/5 |
Fair Price Momentum | 13.58 USD |
Fair Price DCF | - |
EOLS Dividends
No Dividends PaidEOLS Growth Ratios
Growth Correlation 3m | 62.7% |
Growth Correlation 12m | 15.3% |
Growth Correlation 5y | 66.9% |
CAGR 5y | 30.13% |
CAGR/Max DD 5y | 0.44 |
Sharpe Ratio 12m | -0.54 |
Alpha | -19.94 |
Beta | 1.47 |
Volatility | 59.54% |
Current Volume | 827k |
Average Volume 20d | 727.6k |
What is the price of EOLS stocks?
As of March 15, 2025, the stock is trading at USD 13.20 with a total of 827,049 shares traded.
Over the past week, the price has changed by -2.80%, over one month by -10.45%, over three months by +14.68% and over the past year by -6.18%.
As of March 15, 2025, the stock is trading at USD 13.20 with a total of 827,049 shares traded.
Over the past week, the price has changed by -2.80%, over one month by -10.45%, over three months by +14.68% and over the past year by -6.18%.
Is Evolus a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Evolus is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.88 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EOLS as of March 2025 is 13.58. This means that EOLS is currently overvalued and has a potential downside of 2.88%.
Neither. Based on ValueRay Fundamental Analyses, Evolus is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.88 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EOLS as of March 2025 is 13.58. This means that EOLS is currently overvalued and has a potential downside of 2.88%.
Is EOLS a buy, sell or hold?
Evolus has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy EOLS.
Evolus has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy EOLS.
- Strong Buy: 3
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for EOLS stock price target?
According to ValueRays Forecast Model, EOLS Evolus will be worth about 15.3 in March 2026. The stock is currently trading at 13.20. This means that the stock has a potential upside of +15.83%.
According to ValueRays Forecast Model, EOLS Evolus will be worth about 15.3 in March 2026. The stock is currently trading at 13.20. This means that the stock has a potential upside of +15.83%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 24.1 | 82.9% |
Analysts Target Price | 23.4 | 77.5% |
ValueRay Target Price | 15.3 | 15.8% |